Cidara Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
Cidara Therapeutics (Nasdaq: CDTX) is set to present at the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021, at 1:30 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cidara Therapeutics (Nasdaq: CDTX) is set to present at the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021, at 1:30 PM ET. CEO Jeffrey Stein will provide a corporate overview highlighting the company’s commitment to developing long-acting therapeutics for severe fungal and viral infections. Cidara's lead candidate is rezafungin, part of its innovative Cloudbreak® antiviral platform. Investors can access the live audio webcast on the company’s website.
Details
News Market Reaction – CDTX
The recorded move for CDTX in the trading session of this news was -4.96%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021.
| Presentation Information: | |
| Date: | Wednesday, April 14, 2021 |
| Time: | 1:30 PM ET |
| Webcast: | A live audio webcast and replay of the presentation will be available in the Investors section on the company’s website at www.cidara.com. |
About Cidara Therapeutics
Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases from Cidara’s proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Patrick Bursey
LifeSci Communications
(203) 430-9545
pbursey@lifescicomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.